Brief: Caliway Says A Phase 2B Study For Reducing Abdominal Subcutaneous Fat Met All Main Goals
11/12/2024 14:56
Dec 11 (Reuters) - Caliway Biopharmaceuticals Co Ltd
6919.TW :
* CALIWAY ANNOUNCES SUCCESSFUL STUDY RESULTS FROM CBL-0204,
A
CBL-514 PHASE 2B STUDY FOR REDUCING ABDOMINAL SUBCUTANEOUS FAT,
MET ALL PRIMARY AND SECONDARY EFFICACY ENDPOINTS
* CALIWAY - COMPARED TO PLACEBO GROUP, CBL-514 REDUCES OVER
30%
OF ABDOMINAL FAT THICKNESS IN PP POPULATION
Source text: ID:nPn2wY5fDa
Further company coverage: 6919.TW
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CALIWAY BIOPHARMACEUTICALS
See all newsBrief: Caliway: New Drug CBL-514 Phase II Clinical Results' Demonstrated Efficacy
Brief: Caliway Says A Phase 2B Study For Reducing Abdominal Subcutaneous Fat Met All Main Goals
Brief: Caliway Announced EMA Orphan Drug Designation Granted To CBL-514 For Dercum's Disease Treatment
Brief: Caliway Biopharmaceuticals Expects IND Approvals For Cbl-514